Long-term Health Outcomes

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Amgen plans to use lower starting doses with gradual escalation to improve tolerability ahead of expanded Phase 3 studies